Glenmark Pharmaceuticals Ltd.’s remogliflozin appears to have made noteworthy progress in India, with the new entrant garnering the highest prescriptions in the sodium glucose co-transporter-2 (SGLT2) inhibitor segment for the second month on the trot.
Remogliflozin (marketed as Remo) recorded 90,100 prescriptions in October 2019, higher than some established competitors such as Boehringer Ingelheim...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
